HC Wainwright Predicts Weaker Earnings for BioLife Solutions

BioLife Solutions, Inc. (NASDAQ:BLFS) – HC Wainwright cut their Q3 2026 earnings estimates for shares of BioLife Solutions in a research report issued on Tuesday, May 27th. HC Wainwright analyst Y. Chen now expects that the medical equipment provider will post earnings per share of $0.00 for the quarter, down from their previous forecast of $0.03. HC Wainwright currently has a “Buy” rating and a $30.00 price target on the stock. The consensus estimate for BioLife Solutions’ current full-year earnings is ($0.30) per share. HC Wainwright also issued estimates for BioLife Solutions’ FY2026 earnings at ($0.01) EPS.

BioLife Solutions (NASDAQ:BLFS) last issued its quarterly earnings results on Thursday, May 8th. The medical equipment provider reported $0.04 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.03) by $0.07. The company had revenue of $23.94 million during the quarter, compared to analyst estimates of $22.22 million. BioLife Solutions had a negative net margin of 38.98% and a negative return on equity of 6.61%.

Separately, Wall Street Zen downgraded shares of BioLife Solutions from a “hold” rating to a “sell” rating in a research report on Wednesday, May 21st. One research analyst has rated the stock with a sell rating and six have given a buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $31.17.

BioLife Solutions Stock Down 0.1%

Shares of BioLife Solutions stock opened at $22.32 on Wednesday. The company has a debt-to-equity ratio of 0.03, a current ratio of 2.78 and a quick ratio of 1.78. The company has a 50-day moving average of $22.94 and a 200 day moving average of $25.09. The firm has a market cap of $1.06 billion, a price-to-earnings ratio of -21.06 and a beta of 2.01. BioLife Solutions has a 1 year low of $18.70 and a 1 year high of $29.55.

Insider Activity

In other news, EVP Aby J. Mathew sold 1,597 shares of the firm’s stock in a transaction dated Tuesday, March 11th. The shares were sold at an average price of $25.00, for a total transaction of $39,925.00. Following the sale, the executive vice president now owns 260,601 shares of the company’s stock, valued at $6,515,025. This trade represents a 0.61% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CFO Troy Wichterman sold 4,151 shares of the firm’s stock in a transaction dated Tuesday, March 11th. The shares were sold at an average price of $25.00, for a total transaction of $103,775.00. Following the sale, the chief financial officer now directly owns 116,809 shares in the company, valued at approximately $2,920,225. The trade was a 3.43% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 71,696 shares of company stock valued at $1,665,094 in the last 90 days. 2.20% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the business. Steward Partners Investment Advisory LLC bought a new position in BioLife Solutions in the fourth quarter worth approximately $26,000. Point72 Asia Singapore Pte. Ltd. bought a new position in BioLife Solutions in the fourth quarter worth approximately $31,000. State of Wyoming raised its position in BioLife Solutions by 353.1% in the first quarter. State of Wyoming now owns 1,912 shares of the medical equipment provider’s stock worth $44,000 after acquiring an additional 1,490 shares during the period. US Bancorp DE raised its position in BioLife Solutions by 243.7% in the first quarter. US Bancorp DE now owns 2,155 shares of the medical equipment provider’s stock worth $49,000 after acquiring an additional 1,528 shares during the period. Finally, 1620 Investment Advisors Inc. raised its position in BioLife Solutions by 41.7% in the fourth quarter. 1620 Investment Advisors Inc. now owns 2,295 shares of the medical equipment provider’s stock worth $60,000 after acquiring an additional 675 shares during the period. 93.24% of the stock is currently owned by institutional investors.

About BioLife Solutions

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.